วัคซีนโควิด-19
แหล่งข้อมูลอื่น

↑  "Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial". en.irct.ir. Iran Registry of Clinical Trials. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-04-28. สืบค้นเมื่อ 2021-03-21.
↑  
"Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine (COVID-19)". ClinicalTrials.gov. 2021-07-15. NCT04962893. สืบค้นเมื่อ 2021-07-15.
↑  
"Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults (COVID-19)". ClinicalTrials.gov. 2021-03-26. NCT04818281. สืบค้นเมื่อ 2021-04-03.
↑  
"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19". ClinicalTrials.gov. 2021-07-26. NCT04977024. สืบค้นเมื่อ 2021-07-26.
↑  
"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19". ClinicalTrials.gov. 2020-11-20. NCT04639466. สืบค้นเมื่อ 2021-03-21.
↑  "Another Chinese adenovirus vector COVID-19 vaccine ready for human trials". Xinhua. 2020-12-28. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-27. สืบค้นเมื่อ 2021-07-27.
↑  "A Phase II Clinical Trial of the Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector)". chictr.org.cn. 2021-08-02. ChiCTR2100049530. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-23. สืบค้นเมื่อ 2021-08-02.
↑  "Phase I Clinical Trial of the Candidate Recombinant SARS-CoV-2 Vaccine (Chimpanzee Adenoviral Vector)". chictr.org.cn. 2021-05-23. ChiCTR2100046612. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-18. สืบค้นเมื่อ 2021-05-23.
↑  "Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial". Bavarian Nordic. 2021-03-08. สืบค้นเมื่อ 2021-04-13.
↑  
"Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine". Bavarian Nordic. 2021-08-23. สืบค้นเมื่อ 2021-08-24.
↑  
"Safety and Tolerability of ABNCoV2 (COUGH-1)". ClinicalTrials.gov. 2021-04-09. NCT04839146. สืบค้นเมื่อ 2021-04-13.
↑  
"Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus' Investigational mRNA Vaccines for COVID-19". Business Wire. 2021-08-02.
↑  
"Arcturus Allows Vietnam's Vingroup to Make Covid Vaccines". Bloomberg. 2021-08-02.
↑  
"Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus' mRNA Covid-19 vaccine". Yahoo! Finance. 2021-08-02.
↑  
"Arcturus to start clinical trial of COVID-19 vaccine in Vietnam". Reuters. 2021-08-02.
↑  
"Arcturus Therapeutics lines up Phase 1/2/3 trial for next-generation mRNA COVID-19 vaccine". Biopharma Reporter. 2021-08-02.
↑  "The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (ARCT-154-01)". United States National Library of Medicine. 2021-08-19. NCT05012943. สืบค้นเมื่อ 2021-08-19.
↑  "Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern". Clover Biopharmaceutical. 2021-05-18. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-09. สืบค้นเมื่อ 2021-07-09.
↑  
"Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults". United States National Library of Medicine. 2021-07-06. NCT04950751. สืบค้นเมื่อ 2021-07-06.
↑  "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC". ClinicalTrials.gov. 2021-04-05. NCT04830800. สืบค้นเมื่อ 2021-04-13.
↑  "Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand". ClinicalTrials.gov. 2021-02-21. NCT04764422. สืบค้นเมื่อ 2021-04-07.
↑  
"Vaccine COVID-19 "made in Vietnam" COVIVAC thử nghiệm giai đoạn 2". VTV. 2021-08-10. สืบค้นเมื่อ 2021-08-12.
↑  
Zimmer, Carl (2021-04-05). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. สืบค้นเมื่อ 2021-04-07.
↑  
"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19". ClinicalTrials.gov. 2021-05-03. NCT04869592. สืบค้นเมื่อ 2021-05-04.
↑  
"CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". UK BioIndustry Association. 2020-08-13. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-23.
↑  
"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-23.
↑  "Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021". ClinicalTrials.gov. 2021-01-28. NCT04728347. สืบค้นเมื่อ 2021-03-13.
↑  "A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults". ClinicalTrials.gov. 2020-12-16. NCT04668339. สืบค้นเมื่อ 2021-03-10.
↑  
"VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines (Press release). 2021-03-09. สืบค้นเมื่อ 2021-03-22.
↑  "Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)". ClinicalTrials.gov. 2021-02-26. NCT04773665. สืบค้นเมื่อ 2021-03-15.
↑  "Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate". Novavax. 2021-05-10.
↑  "Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine". ClinicalTrials.gov. 2021-07-14. NCT04961541. สืบค้นเมื่อ 2021-07-26.
↑  "Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate" (Press release). Sanofi. 2021-03-12. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-04-27. สืบค้นเมื่อ 2021-03-20.
↑  "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)". ClinicalTrials.gov. 2021-03-15. NCT04798027. สืบค้นเมื่อ 2021-03-20.
↑  "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 2021-03-05. NCT04783311. สืบค้นเมื่อ 2021-03-20.
↑  "Trial registered on ANZCTR". anzctr.org.au. Australian New Zealand Clinical Trials Registry. สืบค้นเมื่อ 2021-03-24.
↑  
"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-06-24. NCT04445389. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. 2021-01-20. NCT04715997. สืบค้นเมื่อ 2021-03-16.
↑  
"S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 2020-06-19. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-06-25.
↑  
"Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 2020-06-11. สืบค้นเมื่อ 2020-08-01.
↑  
"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals". ClinicalTrials.gov. 2021-06-07. NCT04915989. สืบค้นเมื่อ 2021-06-08.
↑  
"Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults". ClinicalTrials.gov. 2020-05-13. NCT04386252. สืบค้นเมื่อ 2021-03-23.
↑  
"Dendritic Cell Vaccine to Prevent COVID-19". ClinicalTrials.gov. 2020-12-28. NCT04685603. สืบค้นเมื่อ 2021-03-23.
↑  "Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers". ClinicalTrials.gov. 2021-03-09. NCT04788459. สืบค้นเมื่อ 2021-03-21.
1 2  "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19". ClinicalTrials.gov. 2021-02-12. NCT04751682. เก็บจากแหล่งเดิมเมื่อ 2021-02-24.
↑  "Intranasal Vaccine For Covid-19". Bharat Biotech. สืบค้นเมื่อ 2021-03-05.
↑  
Gaurav, Kunal (2021-08-13). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times (ภาษาอังกฤษ).
↑  
"ChulaCov19 mRNA Vaccine in Healthy Adults". ClinicalTrials.gov. 2020-09-28. NCT04566276. สืบค้นเมื่อ 2021-03-21.
1 2  
"Safety and Immunity of Covid-19 aAPC Vaccine". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-03-09. NCT04299724. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
1 2  "About Us". Shenzhen Genoimmune Medical Institute. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-01.
1 2  
"Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-02-19. NCT04276896. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults". ClinicalTrials.gov. 2021-01-14. NCT04710303. สืบค้นเมื่อ 2021-03-23.
↑  
"COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA". ClinicalTrials.gov. 2021-02-01. NCT04732468. สืบค้นเมื่อ 2021-03-23.
↑  
"COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers". ClinicalTrials.gov. 2020-10-19. NCT04591717. สืบค้นเมื่อ 2021-03-23.
↑  
"COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines". ClinicalTrials.gov. 2021-04-14. NCT04845191. สืบค้นเมื่อ 2021-04-22.
↑  
"COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines". ClinicalTrials.gov. 2021-04-13. NCT04843722. สืบค้นเมื่อ 2021-04-22.
↑  
"Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials". pib.gov.in. Press Information Bureau. สืบค้นเมื่อ 2021-01-13.
↑  "mRNA Vaccines - HGC019". Gennova Biopharmaceuticals Limited. สืบค้นเมื่อ 2021-01-13.
↑  
"Safety and immunogenicity study of an mRNA based vaccine (HGCO19) for COVID19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. สืบค้นเมื่อ 2021-09-09.
↑  
"Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. สืบค้นเมื่อ 2021-06-05.
↑  
"Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". Cochrane COVID-19 Study Register. 2021-08-04. เก็บจากแหล่งเดิมเมื่อ 2021-09-11.
1 2  
"Made-in-Canada coronavirus vaccine starts human clinical trials". cbc.ca. 2021-01-26.
↑  
"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64". ClinicalTrials.gov. 2021-02-21. NCT04765436. สืบค้นเมื่อ 2021-04-22.
1 2  
"VIDO COVID-19 vaccine moves to Phase 1 clinical testing". globalnews.ca. 2021-02-10.
↑  
"A Clinical Trial of COVAC-2 in Healthy Adults". ClinicalTrials.gov. 2021-01-08. NCT04702178. สืบค้นเมื่อ 2021-04-20.
↑  
"Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine". mint. 2020-09-22.
↑  
"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19". ClinicalTrials.gov. 2020-11-06. NCT04619628.
↑  
"A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults". ClinicalTrials.gov. 2021-02-17. NCT04758962.
↑  "COVALIA study update: first healthy volunteers dosed in needle-free SARS-CoV2 DNA vaccine phase 1 trial". Bionet Asia. 2021-06-30. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-19. สืบค้นเมื่อ 2021-07-19.
↑  
"The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers (COVALIA)". ClinicalTrials.gov. 2021-02-08. NCT04742842.
↑  
"Meissa Announces IND Clearance for Phase 1 Study of Intranasal Live Attenuated Vaccine Candidate for COVID-19". Business Wire. 2021-03-16. สืบค้นเมื่อ 2021-03-20.
↑  
"Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". ClinicalTrials.gov. 2021-03-15. NCT04798001. สืบค้นเมื่อ 2021-03-20.
↑  
"Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. สืบค้นเมื่อ 2021-03-21.
↑  
"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers". ClinicalTrials.gov. 2020-07-16. NCT04473690. สืบค้นเมื่อ 2021-03-21.
↑  
"Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". ClinicalTrials.gov. 2020-12-14. NCT04666012. สืบค้นเมื่อ 2021-03-23.
↑  
"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine". ClinicalTrials.gov. 2020-08-21. NCT04522089. สืบค้นเมื่อ 2021-03-21.
↑  
"Anti-COVID19 AKS-452 - ACT Study (ACT)". ClinicalTrials.gov. 2020-12-23. NCT04681092. สืบค้นเมื่อ 2021-03-21.
↑  
"GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)". ClinicalTrials.gov. 2020-12-17. NCT04673149. สืบค้นเมื่อ 2021-03-21.
↑  
"A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults". ClinicalTrials.gov. 2020-10-19. NCT04591184. สืบค้นเมื่อ 2021-03-21.
↑  
"Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)". ClinicalTrials.gov. 2021-02-18. NCT04760743. สืบค้นเมื่อ 2021-03-21.
↑  
"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)". ClinicalTrials.gov. 2020-09-14. NCT04546841. สืบค้นเมื่อ 2021-03-21.
↑  
"B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency (B-pVAC)". ClinicalTrials.gov. 2020-07-08. NCT04954469. สืบค้นเมื่อ 2021-07-08.
↑  
"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19". ClinicalTrials.gov. 2020-04-06. NCT04334980. สืบค้นเมื่อ 2021-03-21.
↑  
"CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) (CORVax12)". ClinicalTrials.gov. 2020-11-13. NCT04627675. สืบค้นเมื่อ 2021-03-21.
↑  
"Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults". ClinicalTrials.gov. 2021-03-01. NCT04776317. สืบค้นเมื่อ 2021-03-22.
↑  
"Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 2020-09-24. NCT04563702. สืบค้นเมื่อ 2021-03-22.
↑  
"Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)". ClinicalTrials.gov. 2021-04-22. NCT04854746. สืบค้นเมื่อ 2021-05-25.
↑  
"SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults". ClinicalTrials.gov. 2021-03-05. NCT04784767. สืบค้นเมื่อ 2021-03-24.
↑  
"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19". ClinicalTrials.gov. 2020-09-29. NCT04569383. สืบค้นเมื่อ 2021-03-24.
↑  
"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 (MVA-SARS-2-ST)". ClinicalTrials.gov. 2021-05-20. NCT04895449. สืบค้นเมื่อ 2021-05-21.
↑  
"Safety, Reactogenicity and Immunogenicity Study of ReCOV". ClinicalTrials.gov. 2021-03-26. NCT04818801. สืบค้นเมื่อ 2021-04-02.
↑  
"Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo". ClinicalTrials.gov. 2021-04-08. NCT04838080. สืบค้นเมื่อ 2021-04-03.
↑  
"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19". ClinicalTrials.gov. 2021-03-24. NCT04813796. สืบค้นเมื่อ 2021-04-13.
↑  "Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID-19 vaccine in Japan" (PDF) (Press release). Daiichi Sankyo. สืบค้นเมื่อ 2021-04-17.
↑  "Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up". Fierce Biotech. 2021-03-22. สืบค้นเมื่อ 2021-04-12.
↑  
"Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects". ClinicalTrials.gov. 2021-03-29. NCT04821674. สืบค้นเมื่อ 2021-04-12.
↑  
"First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects". ClinicalTrials.gov. 2021-05-19. NCT04893512. สืบค้นเมื่อ 2021-05-26.
↑  
"Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 2021-03-22.
↑  "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン（KD-414）の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. สืบค้นเมื่อ 2021-05-07.
↑  
"OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine". BioSpace. 2021-04-01. สืบค้นเมื่อ 2021-04-13.
↑  
"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT 3)". ClinicalTrials.gov. 2021-05-13. NCT04885361. สืบค้นเมื่อ 2021-05-13.
↑  
"Phase 1 Study to Assess Safety, Reactogenicity and Immunogenicity of the HDT-301 Vaccine Against COVID-19". ClinicalTrials.gov. 2021-04-14. NCT04844268. สืบค้นเมื่อ 2021-04-17.
↑  
"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers". ClinicalTrials.gov. 2021-04-09. NCT04839042. สืบค้นเมื่อ 2021-04-17.
↑  
"Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults (COVID-19)". ClinicalTrials.gov. 2021-04-29. NCT04866069. สืบค้นเมื่อ 2021-04-30.
↑  
"Safety and Immunogenicity of EXG-5003". ClinicalTrials.gov. 2021-04-28. NCT04863131. สืบค้นเมื่อ 2021-05-02.
↑  "Randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of mRNACOVID-19 vaccine in healthy susceptible populations aged 18 years and older people". Chinese Clinical Trial Registry (ChiCTR). คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-05-15. สืบค้นเมื่อ 2021-05-15.
↑  "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate". Icosavax. 2021-06-08. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-07-20. สืบค้นเมื่อ 2021-10-09.
↑  
"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine (IVX-411) in Healthy Adults". Australian New Zealand Clinical Trials Registry. สืบค้นเมื่อ 2021-06-14.
↑  "НАЧАТЫ КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ СУБЪЕДИНИЧНОЙ ВАКЦИНЫ ПРОТИВ COVID-19, РАЗРАБОТАННОЙ УЧЁНЫМИ НИИПББ". Biosafty and Biotechnology Journal. 2021-06-15. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-10-26. สืบค้นเมื่อ 2021-10-09.
↑  
"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine". ClinicalTrials.gov. 2021-06-18. NCT04930003. สืบค้นเมื่อ 2021-06-22.
↑  
"Safety and Immunogenicity of LNP-nCOV saRNA-02 Vaccine Against SARS-CoV-2, the Causative Agent of COVID-19 (COVAC-Uganda)". ClinicalTrials.gov. 2021-06-22. NCT04934111. สืบค้นเมื่อ 2021-06-22.
↑  
"IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 2021-06-27. สืบค้นเมื่อ 2021-07-01.
↑  
"A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 2021-06-25. IRCT20210620051639N1. สืบค้นเมื่อ 2021-07-01.
↑  
Rujivanarom, Pratch (2021-06-06). "Local jabs yet to join Covid fight". Bangkok Post. สืบค้นเมื่อ 2021-07-08.
↑  
"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19". ClinicalTrials.gov. 2021-07-07. NCT04953078. สืบค้นเมื่อ 2021-07-07.
↑  
"Phase 1 Intranasal Parainfluenza Virus Type 5-SARS CoV-2 S Vaccine in Healthy Adults (CVXGA1-001)". ClinicalTrials.gov. 2021-07-08. NCT04954287. สืบค้นเมื่อ 2021-07-08.
↑  
"FMBA begins clinical trials of its coronavirus vaccine, press service says". Russian News Agency. 2021-07-19. สืบค้นเมื่อ 2021-07-20.
↑  "Phase I clinical trial to evaluate the safety, tolerability and preliminary immunogenicity of the new coronavirus mRNA vaccine (LVRNA009) in Chinese people aged 18 years and over". chictr.org.cn. 2021-07-31. ChiCTR2100049349. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-03. สืบค้นเมื่อ 2021-07-31.
↑  Limon, Raul (2021-08-12). "First Spanish Covid-19 vaccine approved for human clinical trial". El Pais. สืบค้นเมื่อ 2021-08-15.
↑  
"Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)". clinicaltrials.gov. 2021-08-16. NCT05007509. สืบค้นเมื่อ 2021-08-16.
↑  
"Randomized Controlled-trial to Evaluate Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized". clinicaltrials.gov. 2021-08-23. NCT05016934. สืบค้นเมื่อ 2021-08-23.
↑  "신형코로나비루스후보왁찐을 새로 개발". North's State Commission of Science and Technology. เก็บจากแหล่งเดิมเมื่อ 2021-05-03. สืบค้นเมื่อ 2021-10-09.
↑  "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 2021-04-25. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-04-25. สืบค้นเมื่อ 2021-05-05.
↑  "Dự kiến cuối quý 3-2021, Việt Nam sẽ có vaccine phòng Covid-19 đầu tiên". Nhân Dân. 2021-03-22. สืบค้นเมื่อ 2021-03-25.
↑  "INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies". Inovio Pharmaceutical. 2021-05-12. สืบค้นเมื่อ 2021-06-10.
↑  
"Bangavax Vaccine: Permission sought for clinical trial". thedailystar.net. The Daily Star. 2021-01-18.
↑  
"Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". arabnews.com. Arab News. 2021-01-08.
↑  "Bangavax first buzzed with hope, then fizzled". bdnews24. 2021-05-06. สืบค้นเมื่อ 2021-05-09.
↑  "The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunization" (PDF). Indian Immunologicals. 2020-04-08. คลังข้อมูลเก่าเก็บจากแหล่งเดิม (PDF)เมื่อ 2021-05-11. สืบค้นเมื่อ 2021-07-24.
↑  
Medeiros, Danielle (2020-12-31). "EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19". EpiVax.
↑  
"Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study". CureVac. 2021-05-13.
↑  "Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic's Lead COVID-19 Vaccine Candidate "DYAI-100" and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics". Sorrento Therapeutics. 2021-08-11. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-20. สืบค้นเมื่อ 2021-08-20.
↑  "Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate - DYAI-100 - Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern". Sorrento Therapeutics. 2021-08-19. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-08-19. สืบค้นเมื่อ 2021-08-20.
↑  "Malaysian mRNA vaccine against Covid-19 under development, says Adham". The Edge. 2021-06-21. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-06-29. สืบค้นเมื่อ 2021-06-22.
↑  "Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study". Arcturus Therapeutics. 2021-08-03.
↑  
"Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)". ClinicalTrials.gov. 2020-12-22. NCT04679909. สืบค้นเมื่อ 2021-03-22.
↑  
"Altimmune Announces Update On AdCOVID Phase 1 Clinical Trial". Altimmune. 2021-06-29. สืบค้นเมื่อ 2021-07-01.
↑  
Ward, Denise; McCormack, Sheena (2020-05-22). "Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women". ISRCTN (Registry). doi:10.1186/ISRCTN17072692. ISRCTN17072692.
↑  
"Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)". ClinicalTrials.gov. 2020-08-04. NCT04497298. สืบค้นเมื่อ 2021-03-23.
↑  
"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-08-03. NCT04495933. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-04.
↑  
"UQ-CSL V451 Vaccine". www.precisionvaccinations.com. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2020-12-19. สืบค้นเมื่อ 2020-12-11.
↑  
"Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)". ClinicalTrials.gov. 2020-09-30. สืบค้นเมื่อ 2021-01-26.
↑  "A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)". ClinicalTrials.gov. 2020-08-04. สืบค้นเมื่อ 2021-01-26.
↑  "Participant Enrollment Begins for Phase I Trial of IAVI-Merck COVID-19 Vaccine Candidate". IAVI. สืบค้นเมื่อ 2021-03-14.
↑  "V591 SARS-CoV-2 Vaccine". www.precisionvaccinations.com. คลังข้อมูลเก่าเก็บจากแหล่งเดิมเมื่อ 2021-03-02. สืบค้นเมื่อ 2021-03-14.
↑  "Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates". Merck (Press release). 2021-01-25. สืบค้นเมื่อ 2021-01-25.